Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN [NASD]
AstraZeneca PLC
Index- P/E40.52 EPS (ttm)1.22 Insider Own0.50% Shs Outstand2.62B Perf Week-3.10%
Market Cap132.12B Forward P/E15.39 EPS next Y3.21 Insider Trans0.00% Shs Float2.60B Perf Month-7.40%
Income3.20B PEG2.01 EPS next Q- Inst Own15.80% Short Float2.54% Perf Quarter-8.74%
Sales26.62B P/S4.96 EPS this Y137.20% Inst Trans-6.06% Short Ratio5.35 Perf Half Y-11.49%
Book/sh5.95 P/B8.29 EPS next Y28.97% ROA5.20% Target Price62.35 Perf Year3.61%
Cash/sh2.98 P/C16.53 EPS next 5Y20.20% ROE25.10% 52W Range36.15 - 64.94 Perf YTD-1.36%
Dividend1.40 P/FCF496.69 EPS past 5Y1.70% ROI12.20% 52W High-22.77% Beta0.53
Dividend %2.84% Quick Ratio0.80 Sales past 5Y1.50% Gross Margin80.00% 52W Low38.74% ATR0.94
Employees76100 Current Ratio1.00 Sales Q/Q11.20% Oper. Margin19.40% RSI (14)45.70 Volatility1.65% 1.62%
OptionableYes Debt/Eq1.30 EPS Q/Q223.30% Profit Margin12.00% Rel Volume0.85 Prev Close49.31
ShortableYes LT Debt/Eq1.15 EarningsFeb 11 BMO Payout112.50% Avg Volume12.33M Price50.15
Recom1.60 SMA20-1.29% SMA50-1.45% SMA200-6.40% Volume10,115,966 Change1.71%
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Feb-24-21 02:50PM  
02:16PM  
12:40PM  
12:04PM  
11:56AM  
11:40AM  
11:29AM  
11:05AM  
10:29AM  
09:31AM  
06:50AM  
03:47AM  
03:22AM  
03:03AM  
02:00AM  
Feb-23-21 11:00PM  
09:25PM  
08:54PM  
08:15PM  
07:22PM  
04:55PM  
03:54PM  
03:38PM  
02:08PM  
12:10PM  
11:20AM  
09:43AM  
08:56AM  
04:31AM  
Feb-22-21 09:10PM  
09:03PM  
07:21PM  
04:55PM  
02:33PM  
02:15PM  
01:22PM  
12:30PM  
11:07AM  
11:05AM  
10:55AM  
10:18AM  
09:04AM  
08:06AM  
06:13AM  
05:29AM  
03:29AM  
02:52AM  
01:29AM  
Feb-21-21 07:00PM  
04:27PM  
10:30AM  
08:09AM  
02:16AM  
Feb-20-21 06:45PM  
07:50AM  
06:01AM  
Feb-19-21 11:58PM  
08:36PM  
08:03PM  
02:25PM  
01:00PM  
12:55PM  
12:48PM  
11:45AM  
08:14AM  
07:45AM  
06:20AM  
12:20AM  
Feb-18-21 11:05PM  
08:36PM  
08:12PM  
07:08PM  
07:00PM  
06:35PM  
06:00PM  
01:07PM  
12:36PM  
11:08AM  
09:45AM  
09:25AM  
06:21AM  
05:51AM  
Feb-17-21 08:35PM  
08:00PM  
07:10PM  
07:05PM  
06:45PM  
06:43PM  
06:00PM  
11:40AM  
11:28AM  
10:00AM  
08:54AM  
08:43AM  
07:26AM  
06:55AM  
06:13AM  
03:56AM  
Feb-16-21 09:37PM  
08:07PM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; and AliveCor, Inc. to develop non-invasive potassium monitoring solutions. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.